超越HER2和曲妥珠单抗：异质性、系统生物学和癌症起源研究可能为极早期侵袭性乳腺癌的个性化治疗指引未来方向。 - Suppr

Suppr

超能文献

Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.

作者信息

Roukos Dimitrios H

出版信息

J Clin Oncol. 2010 Jun 10;28(17):e279-80; author reply e282-3. doi: 10.1200/JCO.2009.27.7061. Epub 2010 Apr 20.

DOI:10.1200/JCO.2009.27.7061

PMID:20406920

Abstract

摘要

相似文献

Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.

J Clin Oncol. 2010 Jun 10;28(17):e279-80; author reply e282-3. doi: 10.1200/JCO.2009.27.7061. Epub 2010 Apr 20.

Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report.

Pol J Pathol. 2011;62(1):65-8.

Progression and treatment of HER2-positive breast cancer.

Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20.

Trastuzumab (herceptin) for early-stage breast cancer.

Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. doi: 10.1016/j.hoc.2007.03.003.

Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.

Oncology (Williston Park). 2006 Dec;20(14):1763-71; discussion 1771-2, 1774-6.

Her2-positive breast cancer: herceptin and beyond.

Eur J Cancer. 2008 Dec;44(18):2806-12. doi: 10.1016/j.ejca.2008.09.013. Epub 2008 Nov 18.

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.

Breast. 2006 Apr;15(2):219-25. doi: 10.1016/j.breast.2005.04.017. Epub 2005 Jul 18.

[Molecular subtypes and individualized treatment of breast cancer].

Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):641-4.

Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.

Oncologist. 2007 Dec;12(12):1467-9; author reply 1469-71. doi: 10.1634/theoncologist.12-12-1467.

Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.

Cancer Treat Res. 2009;151:197-215. doi: 10.1007/978-0-387-75115-3_13.

引用本文的文献

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients.

Cancer Control. 2023 Jan-Dec;30:10732748221141672. doi: 10.1177/10732748221141672.

Immunotherapy for Breast Cancer Treatment.

Iran Biomed J. 2021 Mar 8;25(3):140-56. doi: 10.29252/ibj.25.3.140.

A proposal for early and personalized treatment of diabetic retinopathy based on clinical pathophysiology and molecular phenotyping.

Vision Res. 2017 Oct;139:153-160. doi: 10.1016/j.visres.2017.03.006. Epub 2017 Aug 2.

Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance.

Oncol Rep. 2015 Sep;34(3):1146-52. doi: 10.3892/or.2015.4074. Epub 2015 Jun 24.

Potential of antibody-drug conjugates and novel therapeutics in breast cancer management.

Onco Targets Ther. 2014 Mar 24;7:491-500. doi: 10.2147/OTT.S34235. eCollection 2014.

Laparoscopic resections and ENCODE-guided genomics to advance surgery and oncology.

Surg Endosc. 2014 Jul;28(7):2244-6. doi: 10.1007/s00464-014-3456-3. Epub 2014 Feb 25.

Laparoscopic total gastrectomy and gastric cancer genome architecture: lessons, cautions, and promises.

Surg Endosc. 2013 Oct;27(10):3945-7. doi: 10.1007/s00464-013-2988-2. Epub 2013 May 10.

From single protein to colorectal cancer genome landscape and network biology-based biomarkers.

Surg Endosc. 2013 Aug;27(8):3047-8. doi: 10.1007/s00464-013-2852-4. Epub 2013 Feb 27.

Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Cell Cycle. 2013 Jan 15;12(2):225-45. doi: 10.4161/cc.23274. Epub 2012 Jan 15.

Colorectal cancer liver metastases: advances in minimally invasive surgery and genome sequencing-based discoveries.

Surg Endosc. 2013 May;27(5):1848-50. doi: 10.1007/s00464-012-2650-4. Epub 2012 Dec 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.

作者信息

Roukos Dimitrios H

出版信息

J Clin Oncol. 2010 Jun 10;28(17):e279-80; author reply e282-3. doi: 10.1200/JCO.2009.27.7061. Epub 2010 Apr 20.

DOI:10.1200/JCO.2009.27.7061

PMID:20406920

Abstract

摘要

相似文献

Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.

J Clin Oncol. 2010 Jun 10;28(17):e279-80; author reply e282-3. doi: 10.1200/JCO.2009.27.7061. Epub 2010 Apr 20.

Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report.

Pol J Pathol. 2011;62(1):65-8.

Progression and treatment of HER2-positive breast cancer.

Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20.

Trastuzumab (herceptin) for early-stage breast cancer.

Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. doi: 10.1016/j.hoc.2007.03.003.

Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.

Oncology (Williston Park). 2006 Dec;20(14):1763-71; discussion 1771-2, 1774-6.

Her2-positive breast cancer: herceptin and beyond.

Eur J Cancer. 2008 Dec;44(18):2806-12. doi: 10.1016/j.ejca.2008.09.013. Epub 2008 Nov 18.

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.

Breast. 2006 Apr;15(2):219-25. doi: 10.1016/j.breast.2005.04.017. Epub 2005 Jul 18.

[Molecular subtypes and individualized treatment of breast cancer].

Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):641-4.

Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.

Oncologist. 2007 Dec;12(12):1467-9; author reply 1469-71. doi: 10.1634/theoncologist.12-12-1467.

Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.

Cancer Treat Res. 2009;151:197-215. doi: 10.1007/978-0-387-75115-3_13.

引用本文的文献

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients.

Cancer Control. 2023 Jan-Dec;30:10732748221141672. doi: 10.1177/10732748221141672.

Immunotherapy for Breast Cancer Treatment.

Iran Biomed J. 2021 Mar 8;25(3):140-56. doi: 10.29252/ibj.25.3.140.

A proposal for early and personalized treatment of diabetic retinopathy based on clinical pathophysiology and molecular phenotyping.

Vision Res. 2017 Oct;139:153-160. doi: 10.1016/j.visres.2017.03.006. Epub 2017 Aug 2.

Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance.

Oncol Rep. 2015 Sep;34(3):1146-52. doi: 10.3892/or.2015.4074. Epub 2015 Jun 24.

Potential of antibody-drug conjugates and novel therapeutics in breast cancer management.

Onco Targets Ther. 2014 Mar 24;7:491-500. doi: 10.2147/OTT.S34235. eCollection 2014.

Laparoscopic resections and ENCODE-guided genomics to advance surgery and oncology.

Surg Endosc. 2014 Jul;28(7):2244-6. doi: 10.1007/s00464-014-3456-3. Epub 2014 Feb 25.

Laparoscopic total gastrectomy and gastric cancer genome architecture: lessons, cautions, and promises.

Surg Endosc. 2013 Oct;27(10):3945-7. doi: 10.1007/s00464-013-2988-2. Epub 2013 May 10.

From single protein to colorectal cancer genome landscape and network biology-based biomarkers.

Surg Endosc. 2013 Aug;27(8):3047-8. doi: 10.1007/s00464-013-2852-4. Epub 2013 Feb 27.

Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Cell Cycle. 2013 Jan 15;12(2):225-45. doi: 10.4161/cc.23274. Epub 2012 Jan 15.

Colorectal cancer liver metastases: advances in minimally invasive surgery and genome sequencing-based discoveries.

Surg Endosc. 2013 May;27(5):1848-50. doi: 10.1007/s00464-012-2650-4. Epub 2012 Dec 13.